bioAffinity Q3 revenue falls to $1.1M; net loss widens to $5.3M despite CyPath unit sales doubling

bioAffinity Technologies, Inc.

2026-Q3 EPS reported -$23.72 revenue$3,932,386

Q3 2026 total revenue was ~$1.1M vs ~$1.4M a year ago; CyPath Lung testing revenue for the first nine months rose 79% to ~$1.1M.
Net loss was ~$5.3M vs ~$5.1M in Q3 2025; operating loss widened to ~$3.5M from ~$2.3M, with operating expenses ~$4.6M vs ~$3.7M.
CyPath Lung unit sales rose 100% through Q3 vs the first nine months of 2025; ordering physicians increased 89% YoY and existing-physician volume rose 48%.
Cash was ~$2.6M at Sept. 30 vs ~$6.4M at Dec. 31, 2025; the company raised $8.0M gross in August and October 2026 offerings, including ~$4.0M after quarter-end.
Signed an AvMEDICAL distribution agreement targeting VA/government channels; 11 clinical trial sites are active, including nine VA/military centers; patent portfolio has 22 awarded and 36 pending.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.